Voyager Therapeutics (NASDAQ:VYGR)
Historical Stock Chart
1 Year : From Apr 2019 to Apr 2020
By Michael Dabaie
Voyager Therapeutics Inc. (VYGR) shares were up 9% to $26.52 in midday trading Monday.
The clinical-stage gene therapy company said earlier it restructured its gene therapy relationship with Sanofi Genzyme.
Voyager said it is gaining world-wide rights to the VY-HTT01 Huntington's disease program and ex-U.S. rights to the VY-FXN01 Friedreich's ataxia program. Voyager is, in turn, transferring the ex-U.S. rights to VY-FXN01 to Neurocrine Biosciences Inc. (NBIX) under the terms of a collaboration agreement.
Neurocrine shares were up 2.3% to $85.82.
To focus resources on the now wholly-owned Huntington's disease program, Voyager said it would seek a partner to advance its preclinical program for SOD1 amyotrophic lateral sclerosis. Voyager said it no longer expects to file an investigational new drug application with the U.S. Food and Drug Administration for its VY-SOD102 in 2019.
Write to Michael Dabaie at email@example.com
(END) Dow Jones Newswires
June 17, 2019 13:02 ET (17:02 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.